Frazier Life Sciences Management, L.P. Alkermes Plc. Transaction History
Frazier Life Sciences Management, L.P.
- $1.67 Billion
- Q4 2024
A detailed history of Frazier Life Sciences Management, L.P. transactions in Alkermes Plc. stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 601,129 shares of ALKS stock, worth $18.9 Million. This represents 1.04% of its overall portfolio holdings.
Number of Shares
601,129
Previous 576,129
4.34%
Holding current value
$18.9 Million
Previous $16.1 Million
7.21%
% of portfolio
1.04%
Previous 0.87%
Shares
2 transactions
Others Institutions Holding ALKS
# of Institutions
383Shares Held
163MCall Options Held
231KPut Options Held
158K-
Black Rock Inc. New York, NY29.1MShares$914 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.5MShares$581 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD12.3MShares$385 Million0.04% of portfolio
-
State Street Corp Boston, MA8.81MShares$277 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY7.56MShares$237 Million3.55% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $5.16B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...